fr
Article scientifique
Anglais

Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial

Publié dansLancet, vol. 379, no. 9823, p. 1301-1309
Date de publication2012
Résumé

Hepatic veno-occlusive disease is a leading cause of morbidity and mortality after haemopoietic stem-cell transplantation (HSCT). We aimed to assess whether defibrotide can reduce the incidence of veno-occlusive disease in this setting.

Mots-clés
  • Adolescent
  • Bilirubin/blood
  • Child
  • Child, Preschool
  • Female
  • Fibrinolytic Agents/therapeutic use
  • Graft vs Host Disease/epidemiology
  • Hematopoietic Stem Cell Transplantation/adverse effects
  • Hepatic Veno-Occlusive Disease/drug therapy/epidemiology/prevention & control
  • Humans
  • Incidence
  • Infant
  • Infusions, Intravenous
  • Male
  • Multiple Organ Failure/epidemiology
  • Polydeoxyribonucleotides/therapeutic use
  • Renal Insufficiency/epidemiology
Citation (format ISO)
CORBACIOGLU, Selim et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. In: Lancet, 2012, vol. 379, n° 9823, p. 1301–1309. doi: 10.1016/S0140-6736(11)61938-7
Fichiers principaux (1)
Article (Published version)
accessLevelRestricted
Identifiants
ISSN du journal0140-6736
506vues
0téléchargements

Informations techniques

Création10/10/2013 14:46:00
Première validation10/10/2013 14:46:00
Heure de mise à jour14/03/2023 20:38:52
Changement de statut14/03/2023 20:38:50
Dernière indexation16/01/2024 08:16:27
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack